Compare Boston Scientific Corporation (BSX) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Zeta Global Holdings Corp — how do they compare? Boston Scientific Corporation trades at $43.2 (market cap $66.37B), while Zeta Global Holdings Corp trades at $22.42 (market cap $5.62B). The key difference: Boston Scientific Corporation is far larger — about 11.8× Zeta Global Holdings Corp's market cap, and Zeta Global Holdings Corp is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | ZETA | |
|---|---|---|
Market Cap | $66.37B | $5.62B |
Sector | Health | Technology |
52-Week High | $108.14 | $25.24 |
52-Week Low | $42.63 | $14.04 |
Enterprise Value | $75.94B | $5.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
ZETA trades at $21.87, up 1.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats and accelerating revenue growth, reaching $1.3B in 2025. Recent AI partnerships with Palantir and OpenAI signal strategic transformation, though negative net margins and cash flow challenges persist. Technical indicators show bullish moving averages with RSI approaching overbought territory near 70.
ZETA presents growth potential through AI platform expansion but faces profitability challenges. The 27% upside to consensus price target of $27.50 offers opportunity, while negative margins and cash flow require monitoring. Investment thesis hinges on successful AI monetization versus ongoing margin pressure from agency-led channels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
